Coronavirus updates: Barron Trump also tested positive for COVID, Melania says

Melania Trump said she and her son have now tested negative.

A pandemic of the novel coronavirus has now killed more than 1 million people worldwide.

Over 38.4 million people across the globe have been diagnosed with COVID-19, the disease caused by the new respiratory virus, according to data compiled by the Center for Systems Science and Engineering at Johns Hopkins University. The criteria for diagnosis -- through clinical means or a lab test -- has varied from country-to-country. Still, the actual numbers are believed to be much higher due to testing shortages, many unreported cases and suspicions that some national governments are hiding or downplaying the scope of their outbreaks.

The United States is the worst-affected country, with more than 7.9 million diagnosed cases and at least 216,639 deaths.

California has the most cases of any U.S. state, with more than 865,000 people diagnosed, according to Johns Hopkins data. California is followed by Texas and Florida, with over 830,000 cases and over 741,000 cases, respectively.

More than 190 vaccine candidates for COVID-19 are being tracked by the World Health Organization, at least 10 of which are in crucial phase three studies. Of those 10 potential vaccines in late-stage trials, there are currently five that will be available in the United States if approved.


0

'Herd immunity' is not the answer for solving the pandemic, officials say

Promoting the concept of "herd immunity" or "community immunity," a form of indirect protection from infectious disease that occurs when a certain percentage of a population has become immune, is "inappropriate, irresponsible and ill-informed," Thomas M. File Jr., president of the Infectious Diseases Society of America, announced in a statement Wednesday.

While the concept is the goal of vaccination campaigns, it "should never come at the cost of the planned exposure and infection of millions of additional people," File said.

ABC News' Eric Strauss contributed to this report.


Russia prepares to test 2nd COVID-19 vaccine on 40,000 volunteers

Russia has registered a second COVID-19 vaccine and is preparing to test it on 40,000 volunteers, according to Russian officials.

The vaccine, called "EpiVakKorona," was produced by the 'Vector' State Research Center of Virology and Biotechnology in Novosibirsk, a top state lab that since Soviet times has also been a key biological warfare center.

Unlike the first vaccine, Sputnik V, the new vaccine is not based on a modified adenovirus but instead is a "peptide" type vaccine that uses artificially synthesized fragments of the coronavirus itself to produce an immune response. It is administered in two doses, 21 days apart, according to Russian news agency TASS.

Caution must be used when giving it to patients suffering from chronic kidney and liver illnesses, as well as epilepsy and heart illnesses, TASS reported.

So far the vaccine has been tested on about 100 people, but it has not yet passed key clinical trials. The vaccine will now undergo, in effect, a phase 3 trial.

Sputnik V could be widely distributed in Russia by late October or early November, head of the Russian Direct Investment Fund Kirill Dmitriev announced on Monday, according to TASS.

A third Russian vaccine is also on the way -- produced by the M.P. Chumakov Federal Scientific Center for Research and Development of Immuno-biological Drugs, Russian President Vladimir Putin announced Wednesday. A phase 3 trial for that vaccine will begin Monday.

ABC News’ Patrick Reevell contributed to this report.


Funding to be withheld for New York schools in 'red zones'

New York Gov. Andrew Cuomo will withhold funding from schools in "red zones" that remain open –- both public and private –- until matters are resolve to the states liking, Cuomo announced during a conference call Wednesday.

Just over 1,200 people tested positive and seven people died in the state on Tuesday, Cuomo said. The test positivity rate in the "red zone" areas is 6.2%, while the statewide positivity rate excluding Red Zones is .95%.

ABC News’ J. Gabriel Ware contributed to this report.


Trump seeking emergency approval for Regeneron

President Donald Trump is working to get emergency approval for Regeneron, the antibody treatment that he himself received after contracting COVID-19.

The treatment made him "feel very good very fast," he told reporters from the Rose Garden of the White House on Wednesday morning.

"They call it a therapeutic, but I don't think it was therapeutic," Trump said. "I think it was a cure. For me, it was something that was very good. Who knows, maybe it would have happened anyway, maybe I would have recovered beautifully anyway. All I know is once I had Regeneron it worked out very well."


US reports more than 52,000 new cases

There were 52,406 new cases of COVID-19 identified in the United States on Tuesday, according to a real-time count kept by Johns Hopkins University.

The latest daily tally is up by nearly 11,000 from the previous day but still falls under the country’s record set on July 16, when there were 77,255 new cases in a 24-hour-reporting period.

An additional 802 coronavirus-related fatalities were also recorded Tuesday, up by more than 400 from the previous day but down from a peak of 2,666 new fatalities reported on April 17.

A total of 7,858,344 people in the United States have been diagnosed with COVID-19 since the pandemic began, and at least 215,910 of them have died, according to Johns Hopkins. The cases include people from all 50 U.S. states, Washington, D.C. and other U.S. territories as well as repatriated citizens.

By May 20, all U.S. states had begun lifting stay-at-home orders and other restrictions put in place to curb the spread of the novel coronavirus. The day-to-day increase in the country's cases then hovered around 20,000 for a couple of weeks before shooting back up and crossing 70,000 for the first time in mid-July. The daily tally of new cases has gradually come down since then but has started to climb again in recent weeks.